Citigroup has recently reduced Illumina Inc (ILMN) stock to Neutral rating, as announced on December 11, 2024, according to Finviz. Earlier, on November 12, 2024, Morgan Stanley had resumed the stock ...

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

ILMN teams up with NVIDIA to advance technology platforms for the analysis and interpretation of multiomic data.

Claro Advisors LLC lessened its holdings in Illumina, Inc. (NASDAQ:ILMN – Free Report) by 17.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the ...

At the J.P. Morgan Chase Health Care conference in San Francisco on Tuesday, Illumina CEO Jacob Thaysen touched on the ...

Bernstein analyst Eve Burstein maintained a Hold rating on Illumina (ILMN – Research Report) today. The company’s shares opened today at ...

Illumina raises Q4 and FY24 revenue outlook, expects solid margins, with projected 2024 EPS between $4.12 and $4.14.

Illumina Inc (ILMN) stock saw a modest uptick, ending the day at $144.22 which represents a slight increase of $7.53 or 5.51% from the prior close of $136.69. The stock opened at $137 and touched a ...

Illumina, Inc., a leader in DNA sequencing and array technologies, has launched a pilot proteomics program analyzing 50,000 ...

Nvidia partners with industry leaders in life sciences to use AI for drug discovery, genomics research, and healthcare innovation. Read more here.

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of ...